. Author manuscript; available in PMC: 2016 Jul 1.

Published in final edited form as: Stem Cell Res. 2015 May 22;15(1):130–140. doi: 10.1016/j.scr.2015.05.007

Table 1.

Complete blood counts in SRT3025-treated Fancd2^–/– and Fancd2^+/+ mice

	Fancd2^–/– Placebo	Fancd2^–/– SRT3025	P	Fancd2^+/+ Placebo	Fancd2^+/+ SRT3025	P
WBCs, ×10³/μL	6.7 ± 0.5	9.0 ± 0.8	0.02	7.4 ± 0.6	10.1 ± 1.0	0.03
RBCs, ×10⁶/μL	9.9 ± 0.1	10.1 ± 0.1	0.24	10.0 ± 0.1	10.1 ± 0.1	0.45
Hemoglobin, g/dL	15.1 ± 0.1	15.0 ± 0.1	0.52	15.0 ± 0.2	14.8 ± 0.1	0.28
Hematocrit, %	53.6 ± 0.6	54.2 ± 0.7	0.58	54.0 ± 0.7	53.6 ± 0.8	0.71
MCV, fL	54.7 ± 0.4	52.7± 0.5	<0.01	54.0 ± 0.3	52.8 ± 0.3	0.01
Platelets, ×10³/μL	390 ± 12	435 ± 17	0.04	505 ± 22	584 ± 23	0.02

Data were pooled results from multiple mice (14 – 15 mice each group) and presented as mean value ± SEM. WBCs denotes white blood cells; RBCs, red blood cells; MCV, mean corpuscular volume.